A novel breast cancer therapy has been shown to reduce the risk of recurrence for the most common subtype of breast cancer. The specifics of the therapy and its effects are unclear, with various reports mentioning different approaches, including next-gen serds, immunotherapy, and antibody-drug conjugates. The exact reduction in recurrence risk is also uncertain, with one report citing a 30% reduction, while others discuss different methods of preventing cancer relapse.